Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Study Summary

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH). The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH.

Conditions

HIV-1-infection

Interventions / Drugs

Bictegravir Lenacapavir B/F/TAF Placebo to match B/F/TAF Placebo to match BIC/LEN

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment577 participants

Primary Completion—

Lead SponsorGilead Sciences

Data Retrieved2026-04-11 02:55:27.112648+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.